Researchers at Washington University School of Medicine in St. Louis reported preclinical data showing that blocking CXCR3 can reduce T-cell infiltration and limit neurodegeneration in a mouse model of tauopathy. In the study, animals treated with an antibody to CXCR3 over several months showed about a 50% reduction in brain T-cell numbers and improved performance on memory testing. Notably, the approach did not change tau levels in the brain, suggesting the antibody’s effect is aimed at immune-mediated cell death rather than directly reducing pathological tau accumulation. The findings were published in Neuron alongside mechanistic conclusions that the CXCR3 axis is a critical target for mitigating CD4+ and CD8+ T-cell infiltration. For drug developers, the work adds to the growing emphasis on immunology as a modulator of tau-driven degeneration, offering a potential pathway for combination strategies with amyloid-directed agents already used in Alzheimer’s care.